Autoimmunvaskulitiden: Standards und Leitlinien nach EULAR und EUVAS

Translated title of the contribution: Autoimmune vasculitides. Standards and guidelines of EULAR and EUVAS

F. Moosig*, J. U. Holle, W. L. Gross

*Corresponding author for this work
2 Citations (Scopus)


Recently, the European League Against Rheumatism (EULAR) published recommendations on the management of patients with primary systemic vasculitides. The use of the given definitions for different activities and stages of the diseases is encouraged not only in clinical trails but also for the purpose of harmonisation in daily routine. Concerning the diagnostic work-up an interdisciplinary approach in co-operation with expert-centre is recommended. Therapy consists of remission induction and maintenance. For induction therapy in small vessel vasculitis cyclophosphamide or medium potent immunosuppressants such as methotrexate plus glucocorticoids should be used according to disease stage and activity. Glucocorticoids also represent the mainstay of remission induction in large vessel vasculitis. Additional immunosuppressants should be considered, if the disease can not be controlled by glucocorticoids or for the purpose of sparing glucocorticoids. Refractory disease should be treated within clinical trails. Further recommendations deal with monitoring of diseases activity and therapy as well as with measures to avoid complications and late sequelae.

Translated title of the contributionAutoimmune vasculitides. Standards and guidelines of EULAR and EUVAS
Original languageGerman
Issue number3
Pages (from-to)298-309
Number of pages12
Publication statusPublished - 03.2009

Research Areas and Centers

  • Academic Focus: Center for Infection and Inflammation Research (ZIEL)


Dive into the research topics of 'Autoimmune vasculitides. Standards and guidelines of EULAR and EUVAS'. Together they form a unique fingerprint.

Cite this